IL264964A - - Google Patents

Info

Publication number
IL264964A
IL264964A IL26496419A IL26496419A IL264964A IL 264964 A IL264964 A IL 264964A IL 26496419 A IL26496419 A IL 26496419A IL 26496419 A IL26496419 A IL 26496419A IL 264964 A IL264964 A IL 264964A
Authority
IL
Israel
Application number
IL26496419A
Other languages
English (en)
Other versions
IL264964B1 (en
IL264964B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL264964A publication Critical patent/IL264964A/en
Publication of IL264964B1 publication Critical patent/IL264964B1/en
Publication of IL264964B2 publication Critical patent/IL264964B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
IL264964A 2016-08-23 2017-08-22 Anti-CTLA4 and anti-PD1 bifunctional antibody, pharmaceutical preparation thereof and use thereof IL264964B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610705624.2A CN106967172B (zh) 2016-08-23 2016-08-23 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
PCT/CN2017/098466 WO2018036473A1 (zh) 2016-08-23 2017-08-22 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途

Publications (3)

Publication Number Publication Date
IL264964A true IL264964A (cg-RX-API-DMAC7.html) 2019-04-30
IL264964B1 IL264964B1 (en) 2023-06-01
IL264964B2 IL264964B2 (en) 2023-10-01

Family

ID=59334390

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264964A IL264964B2 (en) 2016-08-23 2017-08-22 Anti-CTLA4 and anti-PD1 bifunctional antibody, pharmaceutical preparation thereof and use thereof

Country Status (14)

Country Link
US (2) US11578128B2 (cg-RX-API-DMAC7.html)
EP (1) EP3511346A4 (cg-RX-API-DMAC7.html)
JP (2) JP7425604B2 (cg-RX-API-DMAC7.html)
KR (1) KR102503084B1 (cg-RX-API-DMAC7.html)
CN (1) CN106967172B (cg-RX-API-DMAC7.html)
AU (1) AU2017317124B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019003695A2 (cg-RX-API-DMAC7.html)
CA (1) CA3034850A1 (cg-RX-API-DMAC7.html)
EA (1) EA201990571A1 (cg-RX-API-DMAC7.html)
IL (1) IL264964B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019002254A (cg-RX-API-DMAC7.html)
NZ (2) NZ751904A (cg-RX-API-DMAC7.html)
SG (1) SG11201901583WA (cg-RX-API-DMAC7.html)
WO (1) WO2018036473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN108866635B (zh) * 2017-05-09 2021-11-26 安升（上海）医药科技有限公司 多特异性蛋白药物及其文库、以及制备方法和应用
WO2019042153A1 (zh) 2017-09-01 2019-03-07 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
CA3069238A1 (en) * 2017-11-02 2019-05-09 Systimmune, Inc. Bispecific antibodies and methods of making and using thereof
WO2019179421A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
CN110407942B (zh) * 2018-04-27 2022-02-22 苏州康宁杰瑞生物科技有限公司 针对kn044的单域抗体
TWI831789B (zh) 2018-06-05 2024-02-11 大陸商江蘇康寧杰瑞生物製藥有限公司 二聚體及其用途
CN110684113A (zh) * 2018-07-06 2020-01-14 复旦大学 一种抗PD-1抗原和抗c-Met抗原的双特异性抗体及其构建方法
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
WO2020057610A1 (en) * 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific anti-ctla-4/pd-1 polypeptide complexes
WO2020057611A1 (en) * 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific ctla-4/pd-1 polypeptide complexes
CN111763261B (zh) * 2019-04-02 2022-08-09 杭州尚健生物技术有限公司 一种融合蛋白及其用途
CN112175087B (zh) * 2019-07-02 2022-05-13 深圳市迈加瑞生物技术有限公司 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
KR20220044748A (ko) * 2019-07-11 2022-04-11 우한 이지 바이오파마 씨오., 엘티디. 4가 대칭 이중 특이적 항체
JP7753186B2 (ja) * 2019-08-02 2025-10-14 シーティーティーキュー－アケソ（シャンハイ） バイオメド テク カンパニー リミテッド 抗ｐｄ－１抗体およびその医学的使用
CA3146780A1 (en) * 2019-08-02 2021-02-11 Akeso Pharmaceuticals, Inc. Anti-ctla4/anti-pd-1 bispecific antibody and use thereof
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
CN110563845A (zh) * 2019-09-12 2019-12-13 滨州医学院 抗igsf9抗体、药物组合物及其应用
KR20220104033A (ko) 2019-11-25 2022-07-25 아케소 바이오파마, 인크. 항-pd-1-항-vegfa 이중특이항체, 약학 조성물 및 이의 용도
EP4069746A4 (en) * 2019-12-04 2023-12-27 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. BISPECIFIC FUSION PROTEIN FOR TUMOR TREATMENT
BR112022021426A2 (pt) * 2020-04-22 2022-12-13 Akeso Biopharma Inc Anticorpo biespecífico anti-cd73/anti-pd-1, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico anti-cd73/anti-pd-1, conjugado, kit, usos do anticorpo biespecífico anti-cd73/anti-pd-1, composição farmacêutica, método in vitro, linhagem celular de hibridoma e anticorpo monoclonal anti-cd73
WO2021213523A1 (zh) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
BR112022022020A2 (pt) * 2020-04-29 2023-01-31 Chia Tai Tianqing Pharmaceutical Group Co Ltd Proteína bifuncional contra pd-1 e tgf-ss
CN113577255B (zh) * 2020-04-30 2023-09-08 中国科学院上海药物研究所 肿瘤纳米疫苗、其制备方法及用途
CN113754767A (zh) * 2020-06-03 2021-12-07 上海恒润达生生物科技股份有限公司 抗人pd-1抗体及其用途
CA3189926A1 (en) * 2020-07-27 2022-02-03 Macrogenics, Inc. Methods for the use of a pd-1 x ctla-4 bispecific molecule
CN111944760A (zh) * 2020-08-14 2020-11-17 广东先康达生物科技有限公司 一种分泌双特异性抗体的免疫细胞及其应用
CN112079926A (zh) * 2020-09-17 2020-12-15 北京华大蛋白质研发中心有限公司 抗人ctla4单克隆抗体及其应用
AU2021363350A1 (en) * 2020-10-23 2023-06-22 Akeso Biopharma, Inc Anti-cd73 antibody and use thereof
CN118530341A (zh) * 2021-03-12 2024-08-23 中山康方生物医药有限公司 提高含有免疫球蛋白Fc片段的药物的有效性的方法
KR20230156910A (ko) 2021-03-12 2023-11-15 아케소 바이오파마, 인크. 항-pd-1-항-vegfa 이중특이적 항체를 함유하는 약학적 조합 및 이의 용도
AU2022258365A1 (en) 2021-04-14 2023-11-30 Ad Pharmaceuticals Co., Ltd. Use of antibody in anti-tumor treatment
CN113501879B (zh) * 2021-06-30 2022-09-06 拜盖特生物科技(上海)有限公司 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
US20240352153A1 (en) * 2021-07-23 2024-10-24 Akeso Biopharma, Inc Pharmaceutical composition and use
KR20240083095A (ko) 2021-09-29 2024-06-11 아케소 바이오파마, 인크. 항-lag3 항체, 약학 조성물 및 용도
WO2023143597A1 (en) * 2022-01-30 2023-08-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ctla4/ox40 bispecific antibodies and uses thereof
CN116637182A (zh) 2022-02-24 2023-08-25 康方药业有限公司 包含抗ctla4-抗pd-1双特异性抗体和西奥罗尼的药物组合
WO2024051223A1 (zh) 2022-09-09 2024-03-14 中山康方生物医药有限公司 药物组合及用途
US20240117051A1 (en) * 2022-09-09 2024-04-11 Akeso Biopharma, Inc. Therapeutic combination and use thereof
CN116396392B (zh) * 2023-01-17 2023-10-27 珠海重链生物科技有限公司 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用
AU2024232344A1 (en) * 2023-03-07 2025-10-02 Akeso Pharma Co., Ltd. Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof
KR20250169615A (ko) 2023-04-10 2025-12-03 아케소 파마 컴퍼니, 리미티드 항-ctla4 및 항-pd-1 이중특이성 항체의 의학적 용도
WO2025157267A1 (zh) * 2024-01-25 2025-07-31 中山康方生物医药有限公司 抗pd-1-抗vegfa的双特异性抗体的医药用途
CN120714022A (zh) * 2024-03-27 2025-09-30 康方汇科(上海)生物有限公司 药物组合及用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
KR20130049775A (ko) 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
DK2691112T3 (en) 2011-03-31 2018-07-30 Merck Sharp & Dohme STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
EP2890715B1 (en) 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
EP4285928A3 (en) 2013-09-27 2024-03-13 F. Hoffmann-La Roche AG Anti-pdl1 antibody formulations
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
RU2694981C2 (ru) * 2014-01-03 2019-07-18 Ф. Хоффманн-Ля Рош Аг Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CN104974253A (zh) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CN104987421A (zh) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
CN105175545B (zh) 2015-10-20 2019-01-25 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd-1双功能抗体及其应用
CN105175544B (zh) * 2015-10-20 2021-04-09 安徽瀚海博兴生物技术有限公司 一种抗pd-1人源化单克隆抗体及其应用
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
CN105754990A (zh) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CA3146780A1 (en) 2019-08-02 2021-02-11 Akeso Pharmaceuticals, Inc. Anti-ctla4/anti-pd-1 bispecific antibody and use thereof

Also Published As

Publication number Publication date
IL264964B1 (en) 2023-06-01
US20240010728A1 (en) 2024-01-11
EP3511346A1 (en) 2019-07-17
SG11201901583WA (en) 2019-03-28
CA3034850A1 (en) 2018-03-01
AU2017317124A1 (en) 2019-04-11
AU2017317124B2 (en) 2024-09-26
JP2019533475A (ja) 2019-11-21
US11578128B2 (en) 2023-02-14
NZ751904A (en) 2023-01-27
US20190185569A1 (en) 2019-06-20
MX2019002254A (es) 2019-11-28
EA201990571A1 (ru) 2019-08-30
US12479919B2 (en) 2025-11-25
EP3511346A4 (en) 2020-04-29
KR102503084B1 (ko) 2023-02-24
WO2018036473A1 (zh) 2018-03-01
CN106967172A (zh) 2017-07-21
KR20190052677A (ko) 2019-05-16
IL264964B2 (en) 2023-10-01
CN106967172B (zh) 2019-01-08
JP7425604B2 (ja) 2024-01-31
NZ791621A (en) 2025-10-31
BR112019003695A2 (pt) 2019-06-04
JP2022130393A (ja) 2022-09-06

Similar Documents

Publication Publication Date Title
IL264964A (cg-RX-API-DMAC7.html)
BR112018004966A2 (cg-RX-API-DMAC7.html)
BR102016018018A2 (cg-RX-API-DMAC7.html)
CN303537601S (cg-RX-API-DMAC7.html)
CN303538066S (cg-RX-API-DMAC7.html)
CN303674701S (cg-RX-API-DMAC7.html)
CN303655772S (cg-RX-API-DMAC7.html)
CN303655569S (cg-RX-API-DMAC7.html)
CN303651295S (cg-RX-API-DMAC7.html)
CN303638975S (cg-RX-API-DMAC7.html)
CN303634767S (cg-RX-API-DMAC7.html)
CN303610110S (cg-RX-API-DMAC7.html)
CN303604691S (cg-RX-API-DMAC7.html)
CN303604688S (cg-RX-API-DMAC7.html)
CN303587096S (cg-RX-API-DMAC7.html)
CN303583485S (cg-RX-API-DMAC7.html)
CN303580065S (cg-RX-API-DMAC7.html)
CN303578930S (cg-RX-API-DMAC7.html)
CN303545051S (cg-RX-API-DMAC7.html)
CN303543945S (cg-RX-API-DMAC7.html)
CN303541788S (cg-RX-API-DMAC7.html)
CN303540764S (cg-RX-API-DMAC7.html)
CN303538883S (cg-RX-API-DMAC7.html)
CN303538753S (cg-RX-API-DMAC7.html)
CN303538752S (cg-RX-API-DMAC7.html)